Keyphrases
Chronic Kidney Disease
85%
Enalapril
33%
Glomerular Filtration Rate
32%
Angiotensin-converting Enzyme Inhibitor (ACEi)
29%
Chronic Progressive Nephropathy
28%
Kidney Disease Progression
25%
Renal Function
23%
Confidence Interval
22%
Denmark
21%
Chronic Kidney Disease Stage 3
19%
Atrial Fibrillation
19%
Dialysis
18%
Randomized Controlled Trial
17%
Estimated Glomerular Filtration Rate
16%
National Cohort Study
15%
Proteinuria
15%
Renal Diet
15%
New Nordic
15%
Lupus Nephritis
15%
Transplantation
14%
Kidney Function
13%
Albuminuria
13%
Lithium Clearance
12%
Arterial Stiffness
12%
End-stage Renal Disease
12%
Renal Replacement Therapy
11%
Urinary Excretion
10%
Blood Pressure
10%
Hypertension
10%
Chronic Kidney Disease Patients
10%
Kidney Donor
10%
Hazard Ratio
9%
Stroke Risk
9%
Copenhagen
9%
Angiotensin-converting Enzyme Inhibition
9%
Sodium
9%
Myocardial Infarction
9%
Dialysis-requiring Acute Kidney Injury
9%
Enalaprilat
9%
Type 2 Diabetic Patients
9%
Chronic Kidney Disease Stage
8%
Vitamin K Antagonists
8%
Treatment Effect
8%
Renal Failure
8%
Uninephrectomy
8%
Non-dialysis Chronic Kidney Disease
7%
51Cr-EDTA
7%
Randomized Trial
7%
Chronic Renal Replacement Therapy
7%
Renal Disease
7%
Medicine and Dentistry
Chronic Kidney Disease
100%
Glomerular Filtration Rate
35%
Kidney Function
29%
Nephropathy
24%
Renal Replacement Therapy
21%
ACE Inhibitor
20%
Atrial Fibrillation
18%
Cohort Analysis
16%
Renal Diet
15%
Lupus Nephritis
15%
Apoplexy
13%
End Stage Renal Disease
12%
Urinary Excretion
12%
Pulse Wave Velocity
12%
Proteinuria
11%
Albuminuria
11%
Blood Pressure
10%
Acute Kidney Injury
9%
Dipeptidyl Carboxypeptidase
9%
Kidney Tubule Function
9%
Disease
9%
Patient with Type 2 Diabetes
9%
Vitamin K Antagonist
8%
Antithrombotic
8%
Arterial Stiffness
8%
Urinary System
8%
Uninephrectomy
8%
Enzyme Inhibition
8%
Treatment Effect
8%
Hazard Ratio
7%
Randomized Controlled Trial
7%
Kidney Graft
7%
Reproducibility
7%
Renal Failure
7%
Kidney Transplantation
6%
Enalapril
6%
Aldosterone
6%
Diabetes Mellitus
6%
Kidney Denervation
6%
Thromboembolism
6%
Meta-Analysis
6%
General Medicine
6%
Ferric Carboxymaltose
6%
Tamm Horsfall Glycoprotein
6%
Anticoagulation
6%
Infective Endocarditis
6%
Eplerenone
6%
Epidermal Growth Factor
6%
Iodine 123
6%
Disease Exacerbation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
86%
Enalapril
30%
Dipeptidyl Carboxypeptidase Inhibitor
23%
Cohort Study
20%
Atrial Fibrillation
18%
Kidney Disease
17%
End Stage Renal Disease
14%
Randomized Controlled Trial
14%
Antihypertensive Agent
12%
Heart Infarction
10%
Kidney Failure
9%
Enalaprilat
9%
Antivitamin K
9%
Bleeding
8%
Hemodialysis
8%
Disease
8%
Replacement Therapy
8%
Chromium 51
8%
Ethylenediaminetetraacetic Acid
8%
Thromboembolism
7%
Prevalence
7%
Warfarin
7%
Anticoagulant Agent
7%
Proteinuria
6%
Isotopes of Potassium
6%
Renin
6%
Dipeptidyl Carboxypeptidase
6%
Angiotensin I
6%
Tamm Horsfall Glycoprotein
6%
Candesartan
6%
Epidermal Growth Factor
6%
Ferric Carboxymaltose
6%
Acute Kidney Failure
6%
Endocarditis
6%
Lupus Erythematosus Nephritis
6%
Creatinine
5%
Enzyme Inhibition
5%
